CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
NEEDHAM, Mass., Feb. 13, 2024 -- Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer,...